MedTrace Logo

Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy.

NCT03140176 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 77

Last updated 2024-05-10

Study results available
· View outcomes & findings →

Summary

OPTIMISE is designed to provide knowledge regarding the use of Sunitinib as 1st line treatment and 2nd line treatment selected (Sunitinib-different sequence) with respect to efficacy outcomes, adverse events, and health related QoL in the real life setting.

Conditions

  • Metastatic Renal Cell Carcinoma

Interventions

DRUG

Sunitinib

Sunitinib is an FDA approved targeted therapy for use as first line therapy for patients with metastatic renal cell carcinoma.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-15
Primary Completion
2022-01-22
Completion
2022-01-22
FDA Drug
Yes

Countries

  • Algeria
  • Egypt
  • Kuwait
  • Morocco

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03140176 on ClinicalTrials.gov